Methyl 4-hydroxy-1,2,5,6-tetrahydropyridine-3-carboxylate | 679841-12-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物
• 英文名称: Methyl 4-hydroxy-1,2,5,6-tetrahydropyridine-3-carboxylate
• 英文别名: methyl 4-hydroxy-1,2,3,6-tetrahydropyridine-5-carboxylate
• CAS: 679841-12-4
• 化学式: C₇H₁₁NO₃
• 分子量: 157.17
• InChiKey: MLYDZTDEBFYZHK-UHFFFAOYSA-N

物化性质

• 沸点：
  273.5±40.0 °C(Predicted)
• 密度：
  1.243±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)<br/>[FR] DÉRIVÉS DE 2-[BIS(4-FLUOROPHÉNYL)MÉTHYL]-2,7-DIAZASPIRO[4.5]DÉCAN-10-ONE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE LA PROTÉINE TRANSPORTEUSE ACTIVE DE DOPAMINE (DAT) HUMAINE POUR LE TRAITEMENT PAR EX. D'UN TROUBLE DE DÉFICIT DE L'ATTENTION (TDA)
  申请人：SHIRE INTERNAT GMBH

  公开号：WO2016042451A1

  公开（公告）日：2016-03-24

  The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

  该发明提供了式(I)的化合物，特别是2-[双(4-氟苯基)甲基]-2,7-二氮杂螺[4.5]癸烷-10-酮衍生物及相关化合物，作为人类多巴胺活性转运蛋白（DAT）的抑制剂，用于治疗性功能障碍、情感障碍、焦虑、抑郁、慢性疲劳、图雷特综合征、安吉曼综合征、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、肥胖、疼痛、强迫症、运动障碍、中枢神经系统障碍、睡眠障碍、嗜睡症、行为障碍、物质滥用（包括戒烟）、饮食障碍和冲动控制障碍。
• [EN] Spirocyclic derivatives<br/>[FR] DÉRIVÉS SPIROCYCLIQUES
  申请人：SHIRE INTERNAT GMBH

  公开号：WO2016042452A1

  公开（公告）日：2016-03-24

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

  本发明提供了式(I)的化合物：包含这种化合物的组合物；在治疗中使用这种化合物（例如在通过抑制多巴胺转运体改善的疾病、紊乱或状况的治疗或预防）；以及使用这种化合物治疗患者的方法；其中R1、R2、R3、R4、R5、R6、R9、R10、Q、X、Y、Z、A、L、B、m、n和p如本文所定义。
• 3, 4, 5 - Substituted Piperidine Compounds
  申请人：Masuya Keiichi

  公开号：US20100160305A1

  公开（公告）日：2010-06-24

  3,4,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4,5-substituted piperidine compound, a method for the manufacture of a 3,4,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds are of the formula I, wherein the substitutents are as defined in the specification.
• Spirocyclic derivatives
  申请人：CHRONOS THERAPEUTICS LIMITED

  公开号：US20170253615A1

  公开（公告）日：2017-09-07

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 , Q, X, Y, Z, A, L, B, m, n and p are as defined herein.
• 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)
  申请人：SHIRE INTERNATIONAL GMBH

  公开号：US20170260185A1

  公开（公告）日：2017-09-14

  The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.